Strategy and history
Contera Pharma identifies and develops drug candidates characterized by high probability of success, and long exclusivity targeting indications with high unmet medical need.
Contera Pharma was founded in 2010. The objective was to develop a new treatment of levodopa induced dyskinesia (LID) by combining the target efficacy of two safe known drugs. The two drugs should in a proprietary formulation target mechanism important for the development of LID. JM-010 was identified through a screening of drugs modifying excessive dopamine and glutamate release.
Movement disorders are a group of diseases that affect the ability to produce and control body movement and are often associated with neurological disorders or conditions associated with neurological dysfunction. One example of a movement disorder is dyskinesia which characterized by various involuntary movements, which can affect discrete body parts or can become generalized and severely disabling.
Contera Pharma develops new innovative treatments of movement disorders. The lead project JM-010 is in Phase II clinical studies for treatment of dyskinesia in Parkinson's disease. Contera Pharma in addition, explores preclinical projects to treat or prevent other movement disorders like early morning akinesia associated with Parkinson's disease and tardive dyskinesia.